{"id":"NCT02553798","sponsor":"Journey Medical Corporation","briefTitle":"Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis","officialTitle":"An Open-label Study Assessing Long-term Safety of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-12","completion":"2016-12","firstPosted":"2015-09-18","resultsPosted":"2018-09-25","lastUpdate":"2021-08-25"},"enrollment":564,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hyperhidrosis"],"interventions":[{"type":"DRUG","name":"Glycopyrronium Topical Wipes","otherNames":["DRM04"]}],"arms":[{"label":"Glycopyrronium","type":"EXPERIMENTAL"}],"summary":"This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.","primaryOutcome":{"measure":"Long-term Safety Assessed Through Adverse Events and Local Skin Reactions","timeFrame":"Day 1 - Week 44","effectByArm":[{"arm":"Glycopyrronium","deltaMin":148,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":48,"countries":["United States","Germany"]},"refs":{"pmids":["31111409"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":550},"commonTop":["Dry Mouth","Vision blurred","Application Site Pain","Nasopharyngitis","Mydriasis"]}}